These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Microbiological and immunologic considerations with aerosolized drug delivery. LiPuma JJ Chest; 2001 Sep; 120(3 Suppl):118S-123S. PubMed ID: 11555566 [TBL] [Abstract][Full Text] [Related]
29. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis. Tappenden P; Harnan S; Uttley L; Mildred M; Walshaw M; Taylor C; Brownlee K Pharmacoeconomics; 2014 Feb; 32(2):159-72. PubMed ID: 24338264 [TBL] [Abstract][Full Text] [Related]
30. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Parkins MD; Elborn JS Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231 [TBL] [Abstract][Full Text] [Related]
31. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS. Sands D; Sapiejka E; Gąszczyk G; Mazurek H; J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961 [TBL] [Abstract][Full Text] [Related]
32. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study. Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882 [TBL] [Abstract][Full Text] [Related]
40. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Quittner AL; Buu A Pediatr Pulmonol; 2002 Apr; 33(4):269-76. PubMed ID: 11921456 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]